1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shilpa Medicare Limited

Shilpa Medicare Limited

861.25
INR
+16.30
(+1.93%)
15.33EPS
39.04P/E
117.07BMarket Cap
Nov 06Next Earn
Shilpa Medicare Limited
BSE:SHILPAMED
(Bombay Stock Exchange)

Recent

price

861.25

P/E

ratio

39.04

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
20.98
22.06
25.24
37.25
38.02
41.34
46.86
46.51
42.26
55.13
55.21
68.24
60.11
66.29
65.93
78.64
86.77
Revenue per Share
3.57
2.86
3.22
5.14
4.8
7.03
6.91
6.53
6.88
9.58
9.06
3.63
-1.87
1.84
4.02
12.44
15.33
Basic EPS, GAAP
1.42
3.93
2.97
4.76
4.48
8.35
-5.11
-5.78
-4.45
-13.79
-18.85
-13.57
-2.69
-2.76
-5.72
-1.45
- -
Free Cash Flow per Basic Share
0.13
0.15
0.17
0.25
0.29
0.69
0.35
0.45
- -
1.27
- -
0.54
0.55
- -
- -
0.5
- -
Dividend per Share
31.17
37.51
43.55
53.89
70.32
92.06
123.17
133.09
146.89
163.06
181.37
209.93
205.44
207.49
241.61
132.49
- -
Book Value per Share
30.76
28.95
25.1
36.64
68.53
80.26
109.96
116.27
123.81
132.29
137.56
158.73
149.43
149.03
183.87
96.95
- -
Tangible Book Value per Share
138
144
147
147
154
154
156
161
163
163
163
167
174
174
195
196
194
Basic Weighted Avg Shares
2,903
3,182
3,713
5,482
5,839
6,375
7,301
7,491
6,890
8,989
9,002
11,400
10,434
11,508
12,848
15,380
16,825
Sales/Revenue/Turnover
20.06
15.75
14.51
18.04
18.06
21.74
18.53
15.35
16.92
19.21
13.25
11.04
-0.44
11.63
15.55
17.59
21.96
Operating Margin (%)
130
144
153
232
214
231
306
372
421
438
540
798
955
1,079
1,130
1,197
1,090
Depreciation Expense
493
412
473
757
737
1,083
1,076
1,052
1,123
1,562
1,478
607
-325
319
783
2,433
2,973
Net Income, GAAP
22.83
22.92
16.72
21.27
32.66
25.38
28.7
24.79
19.29
17.81
25.04
40.76
- -
41.19
36
17.61
13.52
Effective Tax Rate (%)
17
12.96
12.75
13.8
12.62
16.99
14.74
14.05
16.29
17.37
16.42
5.32
-3.12
2.77
6.09
15.82
17.67
Profit Margin (%)
982
667
882
669
1,465
1,353
4,930
4,061
2,916
2,130
2,993
2,757
-149
1,827
3,103
2,617
- -
Working Capital
114
51
705
675
163
21
1,425
681
811
1,671
4,758
3,547
2,906
5,614
2,332
1,851
- -
LT Debt
2,262
2,808
3,291
4,065
5,461
7,121
9,841
10,798
11,900
13,215
14,675
18,111
17,744
17,923
23,637
25,912
- -
Total Equity
19.74
12.4
11.03
15.21
12.09
14.02
8.92
6.89
8
9.67
7.13
3.13
- -
3
3.77
7.41
- -
Return on Invested Capital (%)
22.1
13.67
12.07
16.02
13.29
15.89
11.11
8.76
8.86
10.43
8.23
3.54
- -
3.06
4.46
9.08
- -
Return on Capital (%)
30.28
16.47
15.88
21.11
15.7
17.31
12.68
10.16
9.84
12.36
10.53
3.68
-1.8
1.78
3.76
9.82
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
4,747
- -
LT Borrowings
- -
1,838
- -
LT Finance Leases
- -
13
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
196
196
196
Market Capitalization
62,821
68,190
117,065

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
11,098
- -
Cash, Cash Equivalents & STI
- -
917
- -
Accounts Receivable, Net
- -
5,189
- -
Inventories
- -
3,668
- -
Total Current Liabilities
- -
8,481
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
4,747
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.41%
12.78%
9.62%
Free Cash Flow
3.48%
-9%
-74.46%
Net Income, GAAP
-1.66%
-10.82%
210.81%
Sales/Revenue/Turnover
9.95%
11.96%
19.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2,925
3,438
3,193
3,308
12,848
2026
3,215
3,700
4,097
4,370
15,380
2027
4,658
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.73
0.92
1.63
0.74
4.02
2026
2.4
2.25
2.36
5.51
12.44
2027
5.16
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
0.5
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shilpa Medicare Limited manufactures and sells active pharmaceutical ingredients, finished dosage formulations, biologics and biosimilars, and provides contract development and manufacturing organization services to global pharmaceutical companies. The company produces oncology and non-oncology APIs such as anastrozole, capecitabine, gemcitabine HCl, lenalidomide, bendamustine, melphalan, and irinotecan HCl; injectable formulations including azacitidine for injection, bortezomib for injection, busulfan injection, clofarabine injection, decitabine for injection, docetaxel injection, gemcitabine for injection, pemetrexed for injection, and zoledronic acid injection; oral solid formulations such as apremilast tablets, bicalutamide tablets, capecitabine tablets, dimethyl fumarate DR capsules, erlotinib tablets, imatinib mesylate tablets, pirfenidone tablets, prucalopride tablets, thalidomide capsules, tenofovir alafenamide tablets, lenvatinib capsules, teriflunomide tablets, cyclophosphamide capsules, fingolimod capsules, and sunitinib capsules; and other dosage forms including orally disintegrating films, transdermal patches, and lyophilized injectables. It operates in regulated markets worldwide, including the US, Europe, and India, with manufacturing facilities in Raichur and Bengaluru in Karnataka, Jadcherla in Telangana, Nacharam in Hyderabad, and Dabaspet; Shilpa Medicare, founded in 1987 and headquartered in Raichur, Karnataka, India, maintains subsidiaries such as Shilpa Biologicals Pvt Ltd for biologics and Shilpa Pharma Inc in the US. Recent developments include the acquisition of US-based Pilnova Pharma Inc as a wholly owned subsidiary in November 2024 to strengthen US market presence; a May 2025 strategic distribution agreement with Orion Corporation granting exclusive rights to market Shilpa's recombinant human albumin in Europe; a settlement agreement with Celltrion in April 2025; USFDA approval for varenicline tablets in April 2025 and NDA launch of bortezomib for injection in the US in April 2025; European approval for tadalafil orodispersible films in January 2025; and issuance of Europe GMP certificate for Unit VII in Nacharam, Hyderabad, from EMA Austria in December 2024, along with multiple CEP certifications from EDQM for APIs including nifedipine, octreotide, and desmopressin in late 2024.

Company News

Company News APIChatGPT

  • prnewswire.com

    SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America

  • prnewswire.com

    SteinCares et Shilpa Biologicals concluent un accord de licence pour élargir l'accès aux biosimilaires en Amérique latine

  • prnewswire.com

    SteinCares und Shilpa Biologicals schließen Lizenzvereinbarung zur Erweiterung des Zugangs zu Biosimilars in ganz Lateinamerika

  • prnewswire.com

    Shilpa Pharma Lifesciences erhält die EcoVadis-Goldmedaille für herausragende Nachhaltigkeitspraktiken

  • prnewswire.com

    Shilpa Medicare gibt positive Phase-III-Ergebnisse für OERIS™ bekannt - eine neuartige, einmal wöchentlich verabreichte Ondansetron-Injektion mit verlängerter Wirkstofffreisetzung zur Behandlung von Übelkeit und Erbrechen, ausgelöst durch Chemotherapie (CINV)